Kathleen Carpio, DO
Adult Medicine · Neptune, NJNPI 1538694963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,465, 9.5 times the $258 reported in 2020. Among adult medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$706
- Amgen$665
- AbbVie$583
- Exact Sciences$444
- Bayer$396
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,57897%
- Education$431%
- Other$1302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$130
- Otezla$125
- Sucraid$125
- AIRSUPRA$123
- Omnipod$119
- Ozempic$110
- FREESTYLE COPILOT$110
- FreeStyle Libre 2$103
How this compares
$6,751 in reported general payments places this provider in the 90th percentile of 48 adult medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $86,975 |
| JardianceEmpagliflozin | 67 | $66,862 |
| MounjaroTirzepatide | 27 | $43,619 |
| WegovySemaglutide | 13 | $25,144 |
| LinzessLinaclotide | 22 | $18,404 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,584 |
| MyrbetriqMirabegron | 23 | $16,148 |
| Victoza 3-PakLiraglutide | 13 | $11,146 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 15 | $9,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,181 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $5,904 |
| Azelastine Hcl | 61 | $2,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,385 |
| SynthroidLevothyroxine Sodium | 19 | $2,123 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $1,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $706 | $112,11985 claims |
| Boehringer IngelheimJardiance | $87 | $66,86267 claims |
| Lilly USA, LLCMounjaro | $267 | $43,61927 claims |
| AbbVieLinzess, Synthroid | $583 | $20,52841 claims |
| AstraZenecaBreztri Aerosphere | $1,148 | $16,58426 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $16,14823 claims |
| GSKTrelegy Ellipta | $195 | $8,18113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 48 adult medicine providers in New Jersey.
Other adult medicine in Neptune
- Michael HassmanBerlin$14K
- Boris EpsteinE Brunswick$7K
- Michael ReutterBerlin$7K
- Shamim SaeedShrewsbury$6K
- Dimpal RanaClifton$4K
- Leslie SimonsonWest Orange$3K
- Andrea RuizHackensack$2K
- Mary BelloMahwah$2K
- Jolly KuruvillaWest Orange$840
- Julian MaressaBerlin$816
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.